Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma
Authors:
- Omar SarkisOSOmar Sarkis
- Kazem ZibaraKZKazem Zibara
- Steven KregelSKSteven Kregel
- Ali BazarbachiAli Bazarbachi
- Raya SaabRSRaya Saab
- 13 July 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 58 (6) , 877-884
Abstract
Background Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Current treatment strategies do not cure most children with recurrent or high‐risk disease, underlying the need for novel therapeutic approaches. Retinoic acid has been shown to induce differentiation in a variety of cells including skeletal myoblasts and neuroblasts. In the setting of minimal residual disease, retinoic acid improves survival in neuroblastoma, another poorly differentiated childhood tumor. Whether such an approach is useful for rhabdomyosarcoma has not yet been investigated. Several in vitro studies have demonstrated an appreciable effect of retinoic acid on human RMS cellular proliferation and differentiation. Procedure We assessed the efficacy of ATRA on rhabdomyosarcoma, in vitro and in vivo, using cell lines and xenografts. Results ATRA slowed RMS cell proliferation, and promoted a more differentiated myogenic phenotype in both alveolar and embryonal RMS cell lines. Treatment of cultured murine myoblasts with retinoids increased Myogenin expression, but did not induce cell cycle arrest. Despite the favorable in vitro effects, ATRA failed to delay relapse of minimal residual disease using human RMS xenografts in immuno‐suppressed NOD‐SCID (NSG) mice. Interestingly, tumors that recurred after ATRA treatment showed evidence of enhanced muscle differentiation. Conclusion Our results indicate that ATRA could increase the expression of some genes associated with muscle differentiation in rhabdomyosarcoma cells, but there was no benefit of single‐agent therapy in an MRD model, likely because cell cycle arrest was uncoupled from the pro‐differentiation effects of retinoids. Pediatr Blood Cancer 2012; 58: 877–884.Keywords
This publication has 35 references indexed in Scilit:
- Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cellsDifferentiation, 2009
- Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of DiagnosisThe American Journal of Pathology, 2009
- Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtypeJournal of Cancer Research and Clinical Oncology, 2008
- Regulation of cell lineage specification by the retinoblastoma tumor suppressorOncogene, 2006
- Response of human rhabdomyosarcoma cell lines to retinoic acid: Relationship with induction of differentiation and retinoic acid sensitivityExperimental Cell Research, 2005
- Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acidOncogene, 2005
- Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppressionOncogene, 2001
- Rhabdomyosarcoma – working out the pathwaysOncogene, 1999
- Inhibition of Myeloma Cell Growth by All-TransRetinoic Acid is Associated with Upregulatidn of p21 and Dephosphorylation of the Retinoblastoma ProteinLeukemia & Lymphoma, 1999
- Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcomaGenes, Chromosomes and Cancer, 1996